Dr. Hamilton joined Arrowhead in 2013 and now serves as Chief Medical Officer and Head of Research and Development.

He joined Arrowhead as Medical Director, then served as VP of Clinical Development before becoming Chief of Discovery and Translational Medicine in 2020. Effective February 2025, Dr. Hamilton holds the Chief Medical Officer title. He is experienced in multiple disease areas including virology, hepatology, pulmonology, cardiovascular disease, rare disease, and oncology.

Dr. Hamilton led the clinical development of ARO-HBV (now JNJ-3989), licensed to Janssen Pharmaceuticals; and ARO-AAT, licensed to Takeda. He has also served as Head of Corporate Development and led Arrowhead’s in-licensing transaction of Novartis’ RNAi assets, as well as the out-licensing of ARO-LPA (now AMG890) to Amgen. Dr. Hamilton’s involvement in siRNA therapeutics goes back to 2005 when he was CEO of several RNAi therapeutic delivery startups.

Prior to a career in biotech, Dr. Hamilton was an attending emergency medicine physician at a level 1 trauma center in Ohio. He is a licensed physician and has completed residency training with board certification in emergency medicine. He holds both MD and MBA degrees from Ohio State University.

There are many life-threatening conditions where disease biology is well understood, yet there remain no available treatments. The RNAi platform developed at Arrowhead represents a set of new treatment modalities, capable of silencing such undruggable targets, thereby offering the potential of entirely new therapeutic approaches for previously untreatable diseases.